Is microdosing an approved dosing strategy?

No. It is not a labelled regimen. The prescribing information defines a stepped schedule with a specified starting dose; anything below that is off-label and a decision for a prescriber.

Home / Microdosing & compounded

Compounded semaglutide

You are looking into lower-dose or compounded routes.

"Compounded" means a pharmacy prepared the medication rather than the original manufacturer, so it is not an FDA-approved finished product. What is permitted has narrowed sharply — the regulatory position below is current as of August 2026.

Regulatory status of compounded GLP-1s

Current as of August 2026. This area has changed repeatedly — verify before relying on it.

Compounded tirzepatide is generally no longer permitted after the FDA determined the shortage was resolved, with narrow exceptions for documented clinical needs a commercially available product cannot meet.
Compounded semaglutide remains available only through 503A pharmacies preparing patient-specific prescriptions where a documented clinical reason exists — for example a sensitivity to an inactive ingredient, or a dose or delivery form that is not commercially available.
On 30 April 2026 the FDA proposed permanently excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List, the ingredients large-scale outsourcing facilities may use. The agency stated that supply issues, convenience and lower cost do not constitute clinical need. The comment period closed on 30 July 2026.
The FDA issued warning letters to 30 telehealth companies in February 2026, and two of the largest US compounding manufacturers stopped GLP-1 production earlier that year.

The practical effect is that the large-scale, low-cost compounded supply that existed during the shortage has largely gone, and brand-name products now dominate.

This is a summary of publicly reported regulatory developments, not legal advice and not a judgement about any specific pharmacy or product. Whether a particular compounded preparation is lawful for you depends on your prescriber and the pharmacy’s licensing.

Side-by-side

Structural facts from each product’s prescribing information.

Product	Active ingredient	Indication	Frequency	Start	Max labelled	Steps to max
Zepbound Eli Lilly	Tirzepatide	Weight management	Weekly	2.5 mg	15 mg	6
Mounjaro Eli Lilly	Tirzepatide	Type 2 diabetes	Weekly	2.5 mg	15 mg	6
Wegovy Novo Nordisk	Semaglutide	Weight management	Weekly	0.25 mg	2.4 mg	5
Ozempic Novo Nordisk	Semaglutide	Type 2 diabetes	Weekly	0.25 mg	2 mg	4
Saxenda Novo Nordisk	Liraglutide	Weight management	Daily	0.6 mg	3 mg	5
Trulicity Eli Lilly	Dulaglutide	Type 2 diabetes	Weekly	0.75 mg	4.5 mg	4

mg → syringe units converter

U-100 syringe. Formula: (dose ÷ concentration) × 100.

MedicationDose (mg)

Vial concentration (mg/mL)

12.5units on a U-100 syringe

= 0.125 mL · 2.5 mg at 20 mg/mL

Check the concentration printed on the vial you are actually holding. The same dose in milligrams is a completely different mark on the syringe at a different concentration. If the number here does not match what your prescriber told you, trust your prescriber.

Where a compounded product is still lawfully supplied, it may come at a concentration that differs from the branded pens, and that is where the milligram-to-units arithmetic goes wrong. Always convert using the concentration printed on the vial you actually have, not a figure from a forum post.

Common questions

Is microdosing an approved dosing strategy?: No. It is not a labelled regimen. The prescribing information defines a stepped schedule with a specified starting dose; anything below that is off-label and a decision for a prescriber.

Compounded semaglutide

Common questions

Related